Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 10/20 | 0.56 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 6/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.52 |
| ▸ | PRKAG3 | Q9UGI9 | 6/20 | 0.52 |
| ▸ | PRKAG2 | Q9UGJ0 | 6/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391086 | 0.83 | PRKAA2 (0.69) | PRKAA2UTS2RPRKAB2PRKAG1PRKAA1 | |
| Hydrochloric Acid SCHEMBL2391748 | 0.82 | PRKAA2 (0.68) | PRKAA2UTS2RPRKAB2PRKAG1PRKAA1 | |
| SCHEMBL2389715 | 0.78 | SLC6A12 (0.62) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL2390761 | 0.78 | UTS2R (0.65) | PRKAA2UTS2RMEN1KMT2APRKAB2 | |
| SCHEMBL2391731 | 0.77 | PRKAA2 (0.68) | PRKAA2UTS2RMEN1KMT2APRKAB2 | |
| SCHEMBL15817333 | 0.77 | PRKAA2 (0.65) | PRKAA2UTS2RPRKAB2PRKAG1PRKAA1 | |
| SCHEMBL12264881 | 0.76 | HRH3 (0.60) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL15171508 | 0.76 | PRKAA2 (0.65) | PRKAA2KMT2APRKAB2PRKAG1PRKAA1 | |
| SCHEMBL2390055 | 0.76 | MCHR1 (0.59) | PRKAA2UTS2RMEN1KMT2APRKAB2 | |
| SCHEMBL2389604 | 0.76 | KMT2A (0.65) | PRKAA2KMT2APRKAB2PRKAG1PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181220-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140179738-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8697727-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110306767-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-8012955-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306767-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | PRKAA2 7/4885UTS2R 1914/4885MEN1 3006/4885 |
| US-20140179738-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | PRKAA2 7/4885UTS2R 1914/4885MEN1 3006/4885 |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | PRKAA2 7/4885UTS2R 1914/4885MEN1 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.